FRANKFURT (Reuters) – Bayer’s strategic review will take into account a potentially tougher outlook for cash flow, its chief executive said on Tuesday, after abandoning a trial of the blood thinner Asundexian.
Bayer halted a large late-stage clinical trial of a new anticoagulant last Sunday due to a lack of efficacy, calling into question the pharmaceutical group’s most promising development project and worsening its litigation and litigation woes. of debts.
“Anything that has a negative impact on future cash flow makes the situation a little more tense,” Chairman Bill Anderson said on a conference call with analysts Tuesday.
“The impact of these recent events does not change our strategic options. It just means that some of these conditions are a little more stringent,” he added.
Bill Anderson also said he was considering a spinoff of the division that makes over-the-counter health products and crop protection products for agriculture.
(Reporting by Ludwig Burger and Patricia Weiss, French version by Stéphanie Hamel, edited by Kate Entringer)
©2023 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.